Previous close | 16.04 |
Open | 15.74 |
Bid | 14.90 x 600 |
Ask | 14.96 x 600 |
Day's range | 14.72 - 16.05 |
52-week range | 5.26 - 30.96 |
Volume | |
Avg. volume | 776,428 |
Market cap | 894.736M |
Beta (5Y monthly) | 1.85 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
On May 21, 2024, Clay Siegall, President and Chief Executive Officer of Immunome Inc (NASDAQ:IMNM), purchased 100,000 shares of the company, as reported in a recent SEC Filing.
Immunome (IMNM) delivered earnings and revenue surprises of 57.50% and 74.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.